Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 18 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

39%

7 trials in Phase 3/4

Results Transparency

94%

16 of 17 completed trials have results

Key Signals

1 recruiting16 with results

Enrollment Performance

Analytics

Phase 3

7(38.9%)

Phase 2

6(33.3%)

Phase 1

4(22.2%)

N/A

1(5.6%)

18Total

Phase 3(7)

Phase 2(6)

Phase 1(4)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials

NCT06150742Not ApplicableRecruiting

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

Role: lead

NCT02662764Phase 3Completed

Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

Role: lead

NCT02082236Phase 1Completed

Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

Role: lead

NCT02447848Phase 3Completed

Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

Role: lead

NCT02662556Phase 3Completed

A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

Role: lead

NCT02356588Phase 3Completed

A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery

Role: lead

NCT01721070Phase 1Completed

Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

Role: lead

NCT01539642Phase 3Completed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

Role: lead

NCT01660763Phase 3Completed

Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

Role: lead

NCT01639729Phase 1Completed

Effect of Delivery Route on PK of Sufentanil NanoTab

Role: lead

NCT01761565Phase 1Completed

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

Role: lead

NCT01539538Phase 3Completed

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Role: lead

NCT01710345Phase 2Completed

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Role: lead

NCT00718081Phase 2Completed

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery

Role: lead

NCT00833040Phase 2Completed

A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain

Role: lead

NCT00894699Phase 2Completed

A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

Role: lead

NCT00612534Phase 2Completed

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement

Role: lead

NCT00859313Phase 2Completed

An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement

Role: lead

All 18 trials loaded